Gold Nanoshells-Based Lateral Flow Assay for the Detection of Chagas Disease at the Point-of-Care. Academic Article uri icon

Overview

abstract

  • Chagas disease is a neglected parasitic infection and a major public health problem in the Americas. It remains underdiagnosed in the United States and internationally due to the lack of affordable testing and disparities in healthcare, particularly for those most at risk. We describe a proof-of-concept lateral flow immunoassay employing a recombinant Chagas multiantigen conjugated to gold nanoshells (AuNS) to detect circulating human anti-Chagas IgG antibodies. This is one of the first lateral flow immunoassays to capitalize on the larger surface area of AuNS compared with nanoparticles that can help amplify low-magnitude signals. Results were compared with 42 positive and negative Chagas serum samples, of which a subset of 27 samples was validated against an ELISA (Hemagen®). The sensitivity and specificity of our assay were 83% and 95%, respectively. These results suggest that an AuNS-based rapid testing for Chagas disease could facilitate in-field screening/diagnosis with a performance comparable to commercial methods.

publication date

  • June 27, 2022

Research

keywords

  • Chagas Disease
  • Nanoshells
  • Trypanosoma cruzi

Identity

PubMed Central ID

  • PMC9393437

Scopus Document Identifier

  • 85148423604

Digital Object Identifier (DOI)

  • 10.4269/ajtmh.21-1119

PubMed ID

  • 35895419

Additional Document Info

volume

  • 107

issue

  • 2